Direct Reprogramming of Somatic Cells to Schwann Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining Schwann cells for nerve regeneration are invasive, costly, and inefficient, with risks of infection and oncogenesis, and the cells produced lack myelinating ability and immunological compatibility.
Innovation Solution
Direct reprogramming of somatic cells using a combination of SOX10 and KROX20 genes to induce Schwann cell differentiation without pluripotent stem cells, ensuring a low-invasive, immunologically compatible, and efficient production of functional Schwann cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Schwann cells are obtained by harvesting autologous nerves, then the cells can be transplanted for nerve regeneration, but the procedure is extremely invasive and causes secondary nerve damage
Solution Approach 1:
The patent creates copies of Schwann cells through direct reprogramming of somatic cells (such as fibroblasts) by introducing specific transcription factors (SOX10, KROX20, and other specified genes). This produces autologous Schwann cell equivalents without needing to harvest actual nerve tissue, thereby eliminating the invasive procedure and secondary nerve damage while maintaining immunological compatibility
Solution Approach 2:
The patent uses intermediate somatic cells (fibroblasts or other easily obtainable cells) as mediators to generate Schwann cells. These intermediate cells serve as a bridge between easily obtainable tissue samples and the desired Schwann cells, allowing indirect acquisition without direct nerve harvesting
2Reliability
If Schwann cells are separated from autologous nerves and cultured, then the cells can be transplanted, but the number of Schwann cells provided is often insufficient
Solution Approach 1:
The patent performs preliminary expansion of Schwann cells in culture before transplantation. By starting with a small number of harvested cells and expanding them in vitro using defined culture conditions and growth factors, the method produces sufficient cell numbers for transplantation while maintaining the original cells' immunological compatibility
Solution Approach 2:
The patent generates multiple copies of Schwann cells through direct reprogramming of somatic cells. By introducing reprogramming genes into easily obtainable somatic cells, the method produces large numbers of autologous Schwann cell equivalents, solving both the insufficiency problem and maintaining immunological compatibility
3Productivity
If mesenchymal stem cells are used to differentiate Schwann-cell-like cells, then cells can be produced, but the method is costly and time-consuming with quality control difficulties
Solution Approach 1:
The patent changes the key parameter of cell source from difficult-to-obtain mesenchymal stem cells to easily obtainable somatic cells like fibroblasts. This parameter change simplifies the entire process, reduces costs, eliminates quality control issues associated with stem cell sourcing, while still achieving Schwann cell production through direct reprogramming
Solution Approach 2:
The patent uses copying through direct reprogramming of simple somatic cells rather than complex differentiation of stem cells. This approach produces Schwann cell copies more efficiently, with simpler procedures, lower costs, and better quality control, while maintaining the desired cell function
4Productivity
If Schwann cells are created by differentiation methods, then cells can be produced, but the obtained cells lack myelinating ability and may be unable to contribute to saltatory conduction
Solution Approach 1:
The patent changes the fundamental parameter of cell generation method from differentiation (which produces imperfect cells) to direct reprogramming (which produces functional cells). By directly reprogramming somatic cells with specific transcription factors, the method generates Schwann cells with proper myelinating ability and saltatory conduction function, solving the functionality deficit while maintaining efficient production
Data Source
Figure 1~2
Figure 3
Figure 4A
AI summary
The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without passing through pluripotent stem cells, such as ES cells or iPS cells. As a means for solving this problem, the present invention provides a method for preparing Schwann cells that includes a step of introducing into somatic cells of a mammal at least one gene selected from the group consisting of SOX10 genes and KROX20 genes, or an expression product thereof.